BIIB091

Cat. No. M21222

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis.

Molecular Weight	542.64
Formula	C28H34N10O2
CAS Number	2247614-80-6
Solubility (25°C)	DMSO ≥ 100 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related BTK Products
BIIB129 BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells.
UBX-382 UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling.
GDC-0834 GDC-0834 is a potent and selective BTK inhibitor.
DD-03-171 DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM.
N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative.

Catalog